Regeneus has a dynamic Intellectual Property and patent portfolio; we do not just have a single technology. Regeneus is dedicated to generating Intellectual Property and Patents beyond our commercial offerings.
Our IP coverage is broader than our current commercial products and procedures - HiQCell®, CryoShot® and AdiCell®. Our commercial focus for HiQCell is musculoskeletal but our patents cover a very broad range of diseases.
All of our patents are being pursued worldwide. Regeneus holds the registered trademarks for HiQCell, CryoShot and AdiCell.
Regeneus operates within a favourable regulatory environment. The HiQCell and AdiCell procedures fall outside the requirement to register it as a human or veterinary medicine in Australia due to it being an autologous cell therapy, where the cells are harvested and minimally processed in a single procedure under the supervision of a registered practitioner or veterinarian.